Innovative symposium Session Programmes

MONDAY 11 SEPTEMBER, 2017

SESSION 1: TOWARDS SHARED DECISION-MAKING IN PIDD – HOW CAN WE BETTER INVOLVE PATIENTS?

SYMPOSIUM IS ORGANISED BY Shire

Monday 11 September, 15:30-17:00, Pentland Suite

Welcome and introductions

Reinhold E. Schmidt, Germany

Clinical case 1: Theresa, a 45 year-old art therapist with an evolving medical condition

Stephen Jolles, UK

Clinical case 2: Roy, a 24 year-old bus driver with a long history of recurrent infections

Nicholas Brodszki, Sweden

Evaluating a SCIg 20% treatment option

Reinhold E. Schmidt, Germany

Panel questions and answers

All

Summary of key learnings and conclusions

Reinhold E. Schmidt, Germany


TUESDAY 12 SEPTEMBER, 2017

SESSION 2: NEW DEVELOPMENTS IN SECONDARY ANTIBODY DEFICIENCY: 

HOW TO INVESTIGATE AND TREAT ?

SYMPOSIUM IS ORGANISED BY CSL Behring

Tuesday 12 September, 12:45-14:15, Pentland Suite

Chair: Mikko Seppänen, Finland 

Introduction

Mikko Seppänen, Finland

Current Investigation and Treatment of Secondary Antibody Deficiency

Smita Patel, UK

Heart Transplant-Related Secondary Antibody Deficiency: A New Frontier?   

Javier Carbone, Spain

New Secondary Antibody Deficiencies: A Look to the Future

Stephen Jolles, UK

Q&A and Discussion Session

All

Meeting Close

Mikko Seppänen, Finland


WEDNESDAY 13 SEPTEMBER, 2017

SESSION 3: IMMUNOLOGISTS AS ADVISORS ON THE TREATMENT OF SECONDARY IMMUNODEFICIENCY

SYMPOSIUM IS ORGANISED BY Octapharma

Wednesday 13 September, 12:45-14:15, Tinto/Moorfoot Hall

Chair: Isabella Quinti, Italy

Welcome and Introduction

Isabella Quinti, Italy

Secondary Immunodeficiencies: Regulatory Quandaries

Jacqueline Kerr, Germany

Infection Prophylaxis Associated with Secondary Antibody Deficiency in the Context of B-cell Lymphoproliferative Disease

Siraj Misbah, UK

Managing Secondary Immunodeficiency in Transplantation

Javier Carbone, Spain

The Role of Immunologists as Advisors on the Treatment of Secondary Immunodeficiency

Klaus Warnatz, Germany

Secondary Immunodeficiency in Practice

Alex Richter, UK

Closing Remarks

Isabella Quinti, Italy


DISCLOSURE: Although Dr Kerr and Dr Misbah have roles with regulatory authorities, they are not presenting an official regulatory viewpoint at this symposium. They are participating without payment or other support from Octapharma. 

-----------------------------------------------------------------------------------------

SESSION 4EXPANDING SPECTRUM OF AUTOINFLAMMATORY DISEASES

INNOVATION SESSION; FUNDED BY SOBI

Wednesday 13 September, 17:15-18:45, Pentland Suite

Chair: Sinisa Savic, UK

Welcome, Introductions and Aims of The Meeting

Sinisa Savic, UK

'Anticytokine Autoantibodies in Infection and Inflammation

Rainer Doffinger, UK

A New Autoinflammatory Disease Explains Pathogen Sensing by The Pyrin Inflammasome

Seth Masters, Australia

Acquired Autoinflammatory Disorders

Sinisa Savic, UK

Questions and Meeting close 


Keep Me Updated